Doxazosin DOC generic

Doxazosin DOC is a generic pharmaceutical product marketed by DOC Generici, a prominent Italian company specializing in off-patent medications. Doxazosin is primarily used to treat hypertension (high blood pressure) and symptoms of benign prostatic hyperplasia. As a generic manufacturer, DOC Generici focuses on providing high-quality, cost-effective alternatives to branded drugs, leveraging an asset-light model where production is typically outsourced to specialized pharmaceutical manufacturing sites across Italy and other European countries.

Originally founded in 1996 through a joint venture between Chiesi Farmaceutici, Zambon, and Apotex, DOC Generici has grown to become a leader in the Italian generic drugs market. Since its inception, the company has undergone several changes in ownership, moving through private equity firms such as Charterhouse Capital Partners, CVC Capital Partners, and ICG. In 2022, a majority stake was acquired by TPG Capital, a global alternative asset management firm, which continues to oversee the brand's growth and integration into the broader European healthcare market.